NLRP3 and chronic kidney disease: In accordance with the publications employing cultured cells, experimental studies with different CKD models endorse the profibrotic and proinflammatory biological activities of AII, which is described to act as a cytokine, positively regulating renal and immunological cell response of the beneficial effects of RAAS blockade on renal inflammation and fibrosis [33–36].